Liquid chromatography/tandem mass spectrometry method for quantitative estimation of polyethylene glycol 400 and its applications

Bhaskar, V. Vijaya; Middha, Anil; Tiwari, Sudhir; Shivakumar, Savithiri

doi:10.1016/j.jchromb.2013.02.021

Cited by 24 publications

(7 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, a spectrum of different precursors, both protonated and ammoniated, has been described. 4 The mass transition of the designated ammoniated precursor (344.3>89.2) for monitoring PEG 400 corresponds precisely to the one we reported during the validation of our busulfan assay. 3…”

supporting

confidence: 79%

Therapeutic Drug Monitoring of Intravenous Busulfan and Analytical Challenges due to the Drug Formulation Excipient PEG 400: Letter to the Editor

Vethe,

Andersen,

Gedde-Dahl

et al. 2024

Therapeutic Drug Monitoring

View full text Add to dashboard Cite

argument for the formal assignment of TDM leaders who can support the understanding, appropriate use, and adaptation of these tools. The people at the heart of TDM are essential in managing the variability that comes with complex patients. Perhaps, more importantly, they are the key to the successful and sustained implementation of TDM into clinical workflow.Why the title "Crying over stark differences"? This was the response of our antimicrobial TDM physician on reading the article and recognizing the inequities in the system. We struggle hard to provide an excellent service with the bare minimum funding.

show abstract

supporting

confidence: 79%

Therapeutic Drug Monitoring of Intravenous Busulfan and Analytical Challenges due to the Drug Formulation Excipient PEG 400: Letter to the Editor

Vethe,

Andersen,

Gedde-Dahl

et al. 2024

Therapeutic Drug Monitoring

View full text Add to dashboard Cite

show abstract

“…This in turn can be instrumental in causing matrix effects, thereby weakening the reliability of preclinical pharmacokinetic parameters. This phenomenon has been reported by us for various excipients such as PEG400, cremophor EL and solutol HS15 [ [58] , [59] , [60] , [69] , [70] , [71] , [72] ]. Formulation vehicles could cause 80%–90% ion suppression when administered in both oral and intravenous administration routes [ 63 , 64 , 73 , 74 ].…”

Section: Excipients Causing Bioanalytical Matrix Effectssupporting

confidence: 60%

Three-dimensional aspects of formulation excipients in drug discovery: a critical assessment on orphan excipients, matrix effects and drug interactions

Veeravalli

Cheruvu

Srivastava

et al. 2020

Journal of Pharmaceutical Analysis

View full text Add to dashboard Cite

“…For instance, Bhaskar et al. used the LC–MRM method to quantify PEG 400 in rat plasma [200]. In the plasma, the precursor ions of the nine oligomers derived from the PEG 400 with m/z at 327, 371, 432, 476, 520, 564, 608, 652, and 696 were selected and the product ion at m/z 89 was selected for MRM mode in ESI.…”

Section: Bioanalytical Methods For Polyethylene Glycols and Pegylatedmentioning

confidence: 99%

Recent advances in the bioanalytical methods of polyethylene glycols and PEGylated pharmaceuticals

Zhang

Song

et al. 2020

J of Separation Science

View full text Add to dashboard Cite

Polyethylene glycols are synthetic polymers composed of repeating oxyethylene subunits, which have been known for non-toxic, non-immunogenic, non-antigenic, good solubility in water and therefore approved for pharmaceutical applications. Recently, attachment or amalgamation of polyethylene glycols to therapeutic small molecules, peptides, proteins, or nanoparticles has become a mature technology for the sake of improving their pharmacokinetic and pharmacological profiles, also referred to as PEGylation. By comparison, there are only a few PEGylated pharmaceuticals have been registered for further clinical trials and even less was approved for marketing. High failure rate of PEGylated pharmaceuticals in pre-clinical and clinical trials could be majorly attributed to their unclear pharmacokinetic behaviors. Therefore, the in vivo fate of the PEGylated pharmaceuticals for the various routes of administration needs to be thoroughly investigated An accurate in vivo pharmacological study thereof highly depends on the precise detection of polyethylene glycols as well as their fragments in biological matrixes. The goal of this review is to highlight the analytical methods that were developed and applied to evaluate the polyethylene glycols in pharmaceutical ingredients and excipients, which bring us closer to bridging

show abstract

Liquid chromatography/tandem mass spectrometry method for quantitative estimation of polyethylene glycol 400 and its applications

Cited by 24 publications

References 16 publications

Therapeutic Drug Monitoring of Intravenous Busulfan and Analytical Challenges due to the Drug Formulation Excipient PEG 400: Letter to the Editor

Therapeutic Drug Monitoring of Intravenous Busulfan and Analytical Challenges due to the Drug Formulation Excipient PEG 400: Letter to the Editor

Three-dimensional aspects of formulation excipients in drug discovery: a critical assessment on orphan excipients, matrix effects and drug interactions

Recent advances in the bioanalytical methods of polyethylene glycols and PEGylated pharmaceuticals

Contact Info

Product

Resources

About